‘NewCo Model’ maintains buzz, with debut of Solstice, Slate

Joining the NewCo boom, two more companies have launched this week with assets licensed from Asia and headquarters in the West, bringing the total to five so far in 2026 — a pace that, if maintained, would beat 2025’s bumper year for the strategy.

Last year’s NewCo count came in at 13, more than double the six BioCentury identified in 2024. This year has not only started with five Asia-to-West spinouts in two months, but it has also ushered in the first of neurology and cell therapy NewCos...